These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 18055666

  • 41. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.
    Van Brunt DL, Johnston JA, Ye W, Pohl GM, Sun PJ, Sterling KL, Davis ME.
    Pharmacotherapy; 2005 Nov; 25(11):1541-9. PubMed ID: 16232017
    [Abstract] [Full Text] [Related]

  • 42. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM, Friedman RA, Knilans TK, Black Box Working Group, Section on Cardiology and Cardiac Surgery.
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract] [Full Text] [Related]

  • 43. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S, Kämpf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H.
    Toxicol Lett; 2009 Jan 10; 184(1):38-43. PubMed ID: 19015014
    [Abstract] [Full Text] [Related]

  • 44. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul 28; 50(1291):60. PubMed ID: 18654112
    [No Abstract] [Full Text] [Related]

  • 45. Overcoming the barriers to effective treatment for attention-deficit/hyperactivity disorder: a neuro-educational approach.
    Monastra VJ.
    Int J Psychophysiol; 2005 Oct 28; 58(1):71-80. PubMed ID: 15927296
    [Abstract] [Full Text] [Related]

  • 46. [Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder].
    Kiliç BG, Bilgiç A, Gürkan K, Aysev A.
    Turk Psikiyatri Derg; 2007 Oct 28; 18(3):207-13. PubMed ID: 17853975
    [Abstract] [Full Text] [Related]

  • 47. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.
    J Am Acad Child Adolesc Psychiatry; 2011 Oct 28; 50(10):978-90. PubMed ID: 21961773
    [Abstract] [Full Text] [Related]

  • 48. Growth in stimulant-naive children with attention-deficit/hyperactivity disorder using cross-sectional and longitudinal approaches.
    Hanć T, Cieślik J.
    Pediatrics; 2008 Apr 28; 121(4):e967-74. PubMed ID: 18381524
    [Abstract] [Full Text] [Related]

  • 49. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV, Wilens TE.
    J Clin Psychiatry; 2007 Apr 28; 68 Suppl 11():15-22. PubMed ID: 18307377
    [Abstract] [Full Text] [Related]

  • 50. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample.
    Waring ME, Lapane KL.
    Pediatrics; 2008 Jul 28; 122(1):e1-6. PubMed ID: 18595954
    [Abstract] [Full Text] [Related]

  • 51. Does stimulant treatment lead to substance use disorders?
    Faraone SV, Wilens T.
    J Clin Psychiatry; 2003 Jul 28; 64 Suppl 11():9-13. PubMed ID: 14529324
    [Abstract] [Full Text] [Related]

  • 52. Psychosocial and medical histories of stimulant-treated children.
    Jensen PS, Shervette RE, Xenakis SN, Bain MW.
    J Am Acad Child Adolesc Psychiatry; 1988 Nov 28; 27(6):798-801. PubMed ID: 2904428
    [No Abstract] [Full Text] [Related]

  • 53. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J.
    J Pediatr; 2009 Jul 28; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [Abstract] [Full Text] [Related]

  • 54. Adderall XR: long acting stimulant for single daily dosing.
    Sallee FR, Smirnoff AV.
    Expert Rev Neurother; 2004 Nov 28; 4(6):927-34. PubMed ID: 15853519
    [Abstract] [Full Text] [Related]

  • 55. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 28; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications.
    McAfee AT, Landon J, Jones M, Bangs ME, Acharya N, Hornbuckle K, Wong J.
    Pharmacoepidemiol Drug Saf; 2013 Apr 28; 22(4):386-93. PubMed ID: 23280590
    [Abstract] [Full Text] [Related]

  • 59. Attention deficit hyperactivity disorder, chronic tic disorder, and methylphenidate.
    Gadow KD, Sverd J.
    Adv Neurol; 2006 Apr 28; 99():197-207. PubMed ID: 16536367
    [No Abstract] [Full Text] [Related]

  • 60. Pemoline-associated fulminant liver failure: testing the evidence for causation.
    Berkovitch M, Pope E, Phillips J, Koren G.
    Clin Pharmacol Ther; 1995 Jun 28; 57(6):696-8. PubMed ID: 7781270
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.